tiprankstipranks
Trending News
More News >
Ventas (VTR)
NYSE:VTR
Advertisement

Ventas (VTR) AI Stock Analysis

Compare
1,570 Followers

Top Page

VTR

Ventas

(NYSE:VTR)

Select Model
Select Model
Select Model
Outperform 70 (OpenAI - 4o)
Rating:70Outperform
Price Target:
$75.00
▲(11.72% Upside)
Ventas' overall stock score is driven by strong financial performance and positive earnings call sentiment, indicating robust growth prospects. Technical analysis suggests a neutral trend, while valuation metrics indicate potential overvaluation. The company's strategic initiatives and guidance raise confidence, despite some market challenges.
Positive Factors
Revenue Growth
Strong revenue growth indicates robust demand for Ventas' healthcare properties, enhancing long-term financial stability and shareholder value.
Senior Housing Investments
Increased investment in senior housing with attractive returns positions Ventas for sustained growth, capitalizing on demographic trends like aging population.
Cash Flow Management
Effective cash flow management ensures Ventas can fund operations and investments, supporting long-term strategic initiatives and financial health.
Negative Factors
Rising Debt Levels
High leverage may limit financial flexibility and increase risk, potentially impacting Ventas' ability to invest in growth opportunities.
Post-Acute Asset Dispositions
Dispositions of nonstrategic assets may reduce FFO, impacting short-term financial performance and potentially slowing growth momentum.
Competitive Acquisition Market
Increased competition in acquisitions could pressure Ventas' ability to secure favorable deals, impacting long-term growth and profitability.

Ventas (VTR) vs. SPDR S&P 500 ETF (SPY)

Ventas Business Overview & Revenue Model

Company DescriptionVentas, an S&P 500 company, operates at the intersection of two powerful and dynamic industries: healthcare and real estate. As one of the world's foremost Real Estate Investment Trusts (REIT), we use the power of capital to unlock the value of real estate, partnering with leading care providers, developers, research and medical institutions, innovators and healthcare organizations whose success is buoyed by the demographic tailwind of an aging population. For more than twenty years, Ventas has followed a successful strategy that endures: combining a high-quality diversified portfolio of properties and capital sources to manage through cycles, working with industry leading partners, and a collaborative and experienced team focused on producing consistent growing cash flows and superior returns on a strong balance sheet, ultimately rewarding Ventas shareholders. As of September 30, 2020, Ventas owned or managed through unconsolidated joint ventures approximately 1,200 properties.
How the Company Makes MoneyVentas generates revenue primarily through rental income from its extensive portfolio of healthcare properties. The company enters into long-term leases with operators of healthcare facilities, which typically offer stable and predictable cash flows. In addition to rental income, Ventas may also earn revenue from property management fees and other ancillary services. Key revenue streams include its investments in senior housing, skilled nursing facilities, and research and innovation centers. The company has established strategic partnerships with leading healthcare operators and service providers, enhancing its revenue stability and growth potential. Factors contributing to its earnings include demographic trends such as an aging population, increased demand for healthcare services, and favorable regulatory environments.

Ventas Earnings Call Summary

Earnings Call Date:Jul 30, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Oct 30, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong financial performance with significant growth in SHOP and outpatient medical segments, alongside an increase in investment guidance. However, challenges remain with the headwinds from post-acute asset dispositions and a competitive acquisition market. Overall, the call presents a positive outlook with some caution regarding specific segments.
Q2-2025 Updates
Positive Updates
Strong Earnings Growth
Year-over-year, normalized FFO per share grew 9%, and total company same-store cash NOI increased 7%.
Increased Guidance
Raised full year normalized FFO guidance midpoint to $3.44 per share, representing 8% year-over-year FFO per share growth at the midpoint.
SHOP Segment Performance
SHOP communities in the U.S. delivered 18% same-store cash NOI growth, with revenue growth over 8% for the entire same-store SHOP portfolio.
Senior Housing Investments
Raised full year 2025 senior housing investment volume guidance to $2 billion, with a pipeline of investments expected to yield low to mid-teens unlevered IRR.
Outpatient Medical Growth
Outpatient medical increased same-store occupancy by 20 basis points sequentially and 30 basis points year-over-year to 90.1%.
Negative Updates
Post-Acute Asset Dispositions
Dilutive dispositions of nonstrategic post-acute assets are expected to be a $0.01 FFO headwind per quarter sequentially versus the second quarter.
Challenges in Research Business
Same-store cash NOI in the research business, representing 8% of total, declined less than 1% year-over-year due to lower rents on certain innovation flex space tenants.
Competitive Acquisition Market
Market for senior housing investments has become more competitive, potentially affecting deal pricing and hit rates.
Company Guidance
During Ventas' second quarter 2025 earnings call, the company reported strong financial performance and raised its full-year guidance. Key metrics included a 9% year-over-year growth in normalized funds from operations (FFO) per share, with the full-year normalized FFO guidance midpoint increased to $3.44 per share, representing an 8% growth. Total company same-store cash net operating income (NOI) grew by 7%, driven by a 13.3% increase in the Senior Housing Operating Portfolio (SHOP) and 2.2% growth in the outpatient medical segment. The U.S. SHOP communities achieved 18% same-store cash NOI growth, with a significant 60 basis points sequential improvement in average occupancy in June. Ventas also increased its senior housing investment volume guidance for 2025 to $2 billion, reflecting a robust pipeline of opportunities with low to mid-teens expected unlevered IRRs. The company emphasized its 1-2-3 strategy aimed at driving organic growth, making value-creating investments, and maximizing portfolio performance, positioning Ventas in the upper echelon of REIT growers.

Ventas Financial Statement Overview

Summary
Ventas demonstrates solid financial performance with strong revenue growth and improved profitability margins. The balance sheet shows moderate leverage with a stable equity base. Cash flow metrics are particularly strong, highlighting effective cash management and conversion.
Income Statement
75
Positive
Ventas shows a solid revenue growth trajectory with a TTM revenue growth rate of 4.33%. The gross profit margin has decreased over time, currently at 36.23% in TTM, indicating potential cost pressures. However, the net profit margin improved to 3.61% in TTM, reflecting better profitability management. The EBIT and EBITDA margins are strong, at 14.91% and 37.90% respectively, suggesting efficient operational performance.
Balance Sheet
70
Positive
The company maintains a high debt-to-equity ratio of 1.15 in TTM, which is a slight improvement from previous years, indicating a moderate leverage position. The return on equity has improved to 1.76% in TTM, showing better utilization of equity. The equity ratio stands at 43.54%, reflecting a stable capital structure with a balanced asset funding strategy.
Cash Flow
80
Positive
Ventas exhibits strong cash flow management with a significant free cash flow growth rate of 22.26% in TTM. The operating cash flow to net income ratio is robust at 1.20, indicating strong cash generation relative to net income. The free cash flow to net income ratio of 0.70 suggests effective conversion of earnings into free cash flow.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue5.30B4.92B4.50B4.13B3.83B3.80B
Gross Profit1.92B2.10B770.72M1.85B1.74B1.86B
EBITDA2.01B1.87B1.83B1.62B1.58B1.70B
Net Income191.21M81.15M-40.97M-47.45M49.01M439.15M
Balance Sheet
Total Assets26.47B26.19B24.73B24.16B24.72B23.93B
Cash, Cash Equivalents and Short-Term Investments614.20M897.85M508.79M122.56M149.72M650.88M
Total Debt13.27B13.74B13.69B12.49B12.22B12.11B
Total Liabilities14.55B15.36B15.18B13.94B13.77B13.65B
Stockholders Equity11.53B10.77B9.49B10.15B10.85B10.18B
Cash Flow
Free Cash Flow1.07B725.78M860.46M666.09M593.15M921.53M
Operating Cash Flow1.52B1.33B1.12B1.12B1.03B1.45B
Investing Cash Flow-3.05B-2.38B-184.66M-859.22M-724.14M154.29M
Financing Cash Flow1.59B1.45B-543.75M-283.93M-558.47M-1.30B

Ventas Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price67.13
Price Trends
50DMA
67.59
Negative
100DMA
65.69
Positive
200DMA
64.24
Positive
Market Momentum
MACD
0.16
Positive
RSI
43.70
Neutral
STOCH
25.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VTR, the sentiment is Neutral. The current price of 67.13 is below the 20-day moving average (MA) of 68.14, below the 50-day MA of 67.59, and above the 200-day MA of 64.24, indicating a neutral trend. The MACD of 0.16 indicates Positive momentum. The RSI at 43.70 is Neutral, neither overbought nor oversold. The STOCH value of 25.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for VTR.

Ventas Risk Analysis

Ventas disclosed 52 risk factors in its most recent earnings report. Ventas reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Ventas Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
110.34B137.563.15%1.66%30.73%96.48%
76
Outperform
12.25B26.049.44%6.45%12.73%23.51%
74
Outperform
4.49B24.816.72%6.41%6.89%240.70%
70
Outperform
$31.38B155.701.81%2.74%12.45%
65
Neutral
13.11B79.122.08%6.58%15.91%-49.49%
60
Neutral
6.36B-15.68-8.38%6.47%-7.16%23.40%
65
Neutral
$2.17B12.193.79%4.94%3.15%1.96%
* Real Estate Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
VTR
Ventas
67.13
6.76
11.20%
DOC
Healthpeak Properties
18.47
-2.19
-10.60%
WELL
Welltower
165.19
42.21
34.32%
OHI
Omega Healthcare
41.53
3.83
10.16%
SBRA
Sabra Healthcare REIT
18.71
1.30
7.47%
HR
Healthcare Realty Trust
18.09
1.37
8.19%

Ventas Corporate Events

Private Placements and FinancingBusiness Operations and Strategy
Ventas Amends ATM Sales Agreement to $2.25 Billion
Neutral
Jun 13, 2025

On June 13, 2025, Ventas, Inc. announced an amendment to its ATM Sales Agreement with multiple financial institutions, increasing the aggregate gross sales price of common stock available for issuance to $2.25 billion. This amendment allows Ventas to offer and sell additional shares of common stock, potentially impacting its financial strategy and market presence.

Private Placements and Financing
Ventas Realty Issues $500 Million in Senior Notes
Neutral
Jun 3, 2025

On June 3, 2025, Ventas Realty, a subsidiary of Ventas, Inc., successfully issued and sold $500 million in 5.100% Senior Notes due 2032. The proceeds from this offering are intended for general corporate purposes, including debt repayment, which could impact the company’s financial flexibility and market positioning.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 19, 2025